In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Roche to create companion test for Clovis’ CO1686

Executive Summary

On the same day it received rights to a solid tumor compound from Pfizer Inc., Clovis Oncology Inc. (in-licenses cancer candidates) and Roche Molecular Diagnostics (a division of Roche’s Roche Diagnostics that operates in the US as Roche Molecular Systems Inc.) agreed to develop a companion diagnostic for the biotech’s CO1686 (AVL301), in preclinical studies for advanced non-small cell lung cancer.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register